RxSight (RXST) Income from Continuing Operations (2020 - 2026)
RxSight (RXST) posted Income from Continuing Operations of 15884000.0 for Q1 2026, down 73.56% on a QoQ basis from 9152000.0 in Q4 2025, and down 93.94% year-over-year from 262278145.16 in Q1 2025.
RxSight (RXST) Income from Continuing Operations (2020 - 2026) Analysis & Trends
RxSight's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 15884000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 93.94% year-over-year to 15884000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46638000.0 (down 76.31% YoY) and the FY2025 annual result came in at 38944000.0, down 42.32% from the prior year.
- Income from Continuing Operations was 15884000.0 for Q1 2026 at RxSight, down from 9152000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 53507000.0 in Q4 2022 and bottomed at 17596000.0 in Q1 2022.
- A 5-year average of 4095588.24 and a median of 9816000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 440.07% in 2022, while the deepest fall reached 158.57% in 2022.
- RxSight's Income from Continuing Operations stood at 53507000.0 in 2022, then slipped by 7.23% to 49636000.0 in 2023, then plunged by 111.78% to 5846000.0 in 2024, then tumbled by 56.55% to 9152000.0 in 2025, then tumbled by 73.56% to 15884000.0 in 2026.
- Business Quant data shows RXST's Income from Continuing Operations at 15884000.0 in Q1 2026, 9152000.0 in Q4 2025, and 9816000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn | -15.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.88 Mn |
| Dec 31, 2025 | -9.15 Mn |
| Sep 30, 2025 | -9.82 Mn |
| Jun 30, 2025 | -11.79 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -5.85 Mn |
| Sep 30, 2024 | -6.34 Mn |
| Jun 30, 2024 | -6.08 Mn |
| Mar 31, 2024 | -9.10 Mn |
| Dec 31, 2023 | 49.64 Mn |
| Sep 30, 2023 | -12.42 Mn |
| Jun 30, 2023 | -13.80 Mn |
| Mar 31, 2023 | -13.21 Mn |
| Dec 31, 2022 | 53.51 Mn |
| Sep 30, 2022 | -16.82 Mn |
| Jun 30, 2022 | -16.73 Mn |
| Mar 31, 2022 | -17.60 Mn |
| Dec 31, 2021 | -15.73 Mn |
| Sep 30, 2021 | -12.67 Mn |
| Jun 30, 2021 | -13.48 Mn |